Regeneron's Profit Soared 31% on Higher Collaboration Revenue and Eylea Sales

Regeneron's collaboration revenue more than doubled and Eylea revenue grew by double digits once again, sending profits up by 31%

May 8, 2014 at 11:59AM

Shareholders of Regeneron Pharmaceuticals (NASDAQ:REGN) can certainly see a little clearer now after their company once again delivered impressive growth in the first quarter on the heels of its blockbuster ophthalmic drug, Eylea.

For the quarter, total revenue soared 42% to $626 million from $440 million in the year-ago period. Net product sales of wet aged-related macular degeneration drug Eylea jumped 14% to $359 million in the U.S., but were negatively affected by a decrease in distributor inventory. Sans this impact, Eylea demand improved by 25% year over year. Outside the U.S., net sales of Eylea shot up to $218 million, of which Regeneron, in collaboration with marketing partner Bayer (NASDAQOTH:BAYRY), which is responsible for commercializing Eylea in all ex-U.S. markets, received $61 million for its share of net profit.

Also boosting revenue was a 125% surge in collaborative revenue to $256 million due to the commercialization of Eylea in ex-U.S. countries, and higher research and development reimbursement from its collaboration with Sanofi.

In line with its growing pipeline, R&D and selling, general and administrative expenses rose by 59% and 41%, respectively, from the prior year period.

Profit for the period motored higher by 31% to $263 million, or $2.26 on an adjusted EPS basis, compared to $201 million, or $1.78 in EPS in the year-ago quarter. Regeneron also announced that its cash and marketable securities position improved to $1.18 billion from $1.08 billion in the sequential fourth quarter.

Looking ahead, Regeneron reiterated its previous forecast which calls for $1.7 billion-$1.8 billion in net sales for Eylea.


Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers